Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating anemia

K E King1, P M Ness

  • 1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Hematology/Oncology Clinics of North America
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Transfusion therapy for sickle cell disease (SCD) has proven benefits for acute events like stroke and acute chest syndrome. However, the overall efficacy and risks of chronic transfusions require careful consideration and patient discussion.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lack of cold temperatures is driving recent high-summer warming in the southern Rocky Mountains.

International journal of biometeorology·2025
Same author

Response to: Investigating the neurobehavioral symptoms of neuronopathic Hunter syndrome.

Molecular genetics and metabolism reports·2020
Same author

The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome.

Molecular genetics and metabolism reports·2020
Same author

Blood transfusion safety in sub-Saharan Africa: A literature review of changes and challenges in the 21st century.

Transfusion·2019
Same author

Blood donors with epilepsy continue to face unjustified discriminatory practices.

Vox sanguinis·2018
Same author

A multicentre study investigating vital sign changes occurring in complicated and uncomplicated transfusions.

Vox sanguinis·2017
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Area of Science:

  • Hematology
  • Pediatrics
  • Internal Medicine

Background:

  • Transfusion therapy is a common intervention for sickle cell disease (SCD) and its associated complications.
  • The proven efficacy of transfusion therapy in SCD, particularly for chronic management, remains an area requiring further evidence.
  • Established indications include acute cerebrovascular accidents and acute chest syndrome with respiratory compromise.

Purpose of the Study:

  • To evaluate the established and potential benefits of red cell transfusions in managing sickle cell disease.
  • To highlight the need for careful consideration of risks versus benefits, especially with chronic transfusion protocols.
  • To emphasize the importance of shared decision-making with patients regarding transfusion therapy.

Main Methods:

Related Experiment Videos

  • Review of established clinical practices and evidence for transfusion therapy in sickle cell disease.
  • Analysis of indications for acute and chronic red cell transfusions.
  • Consideration of adverse effects and patient-physician communication.

    • Main Results:

    • Red cell transfusions are definitively indicated for acute stroke and prevention of recurrence in SCD.
    • Transfusions are also indicated for acute chest syndrome with respiratory insufficiency, particularly in pediatric patients.
    • The efficacy of chronic transfusion strategies requires thorough clinical assessment and risk-benefit analysis.

    Conclusions:

    • Transfusion therapy plays a critical role in managing specific acute complications of sickle cell disease.
    • The decision to initiate chronic transfusions in SCD necessitates careful evaluation of the clinical context and potential adverse effects.
    • Informed consent, including a thorough discussion of risks and benefits with the patient, is essential before initiating transfusion therapy.